[ad_1]
QIAGEN N.V. (NYSE: QEN: Frankfurt Prime Standard: QIA) released today
known to be QuantiFERON-TB ® Gold Plus (QFT-Plus), the
Gold standard for accurate and cost effective tests on latent
Tuberculosis infections, by the International Organization for
Migration (IOM) for the detection of tuberculous infections among migrants
has been selected.
As the United Nations Migration Agency, IOM coordinates
Complete medical care of about 20 million worldwide
Migrants, refugees and asylum seekers. The offer of IOM
As part of the five-year global plan to end tuberculosis
2016-2020 The use of QFT-Plus in 16 countries of Africa, Asia
and the Middle East, where public health through tuberculosis
is altered.
QIAGEN fights with governments and internationals
Institutions, non-governmental organizations and partners of the
Economics against the global tuberculosis epidemic. More and more experts in the world
Recognize that for effective TB control,
Laboratory tests for latent TB infections are needed
develop into active and contagious tuberculosis. In the year
In 2018, the World Health Organization (WHO) and the United States Centers for
Disease Control (CDC) already Interferon Gamma Release Assays (IGRA)
such as QFT Plus QIAGEN in the fourth generation and gold QuantiFERON-TB ®
Third generation (QFT) recognized for screening for latent TB.
The International Panel Physicians Association (IPPA) also joined
explicitly pronounced for QFT-Plus.
The full press release can be found here
View the original on businesswire.com: https://www.businesswire.com/news/home/20180730005549/en/
[ad_2]
Source link
